申请人:Davis David Peter
公开号:US20070099871A1
公开(公告)日:2007-05-03
The present invention relates to a compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein: Ar is a substituted aryl or heteroaryl group bearing at least one nitro or azido group or is a group of formula (2) or (3) wherein R
1
, and R
2
, which may be the same or different are independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, aryl, COR
3
or, together with the intervening carbon atom, form an optionally substituted heterocycloalkyl or carbocyclic ring; L is —OC(O)— or —OP(O)(OR
6
)—; n is 0 or 1; X is 0, S, NR
7
or a single covalent bond; R
3
is OR
4
or NR
4
R
5
; R
4
, R
5
, R
6
and R
7
are each independently hydrogen or optionally substituted alkyl or, where R
r
is NR
4
R
5
, R
4
and R
5
can be joined to form, together with the intervening nitrogen atom, a heterocycloalkyl ring; R
8
is hydrogen, alkoxy or dialkylaminoalkyl; R
9
is optionally substituted alkyl; Rio is hydrogen, alkyl, alkoxy or dialkylaminoalkyl; R
11
and R
12
are independently hydrogen, alkyl, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, morpholino, piperidino, piperazino or 1=aziridinyl; A is an optionally substituted aryl or heteroaryl ring; and Dr is a moiety such that DrXH represents a cytotoxic or cytostatic compound.
本发明涉及一种式(1)的化合物或其药学上可接受的盐,其中:Ar是带有至少一个硝基或偶氮基的取代芳基或杂环芳基基团,或是式(2)或(3)中的基团,其中R1和R2,可以相同也可以不同,独立地是可选取代的烷基、可选取代的烯基、可选取代的炔基、芳基、COR3,或者与介于其间的碳原子形成可选取代的杂环烷基或碳环烷基;L是—OC(O)—或—OP(O)(OR6)—;n为0或1;X为0、S、NR7或单一共价键;R3为OR4或NR4R5;R4、R5、R6和R7各自独立地为氢或可选取代的烷基,或者当Rr为NR4R5时,R4和R5可以结合形成介于其间的氮原子的杂环烷基环;R8为氢、烷氧基或二烷基氨基烷基;R9为可选取代的烷基;Rio为氢、烷基、烷氧基或二烷基氨基烷基;R11和R12各自独立地为氢、烷基、烷氧基、硫代烷氧基、氨基、烷基氨基、二烷基氨基、吗啡啉基、哌啶基、哌嗪基或1=氮杂环丙烷基;A为可选取代的芳基或杂环芳基环;Dr是一种基团,使得DrXH代表一种细胞毒性或细胞抑制剂化合物。